• Polaryx Therapeutics named Will Charlton chief medical officer, effective Sept. 1, 2026.
• Appointment positions the company for a planned SOTERIA Phase 2 trial initiation in Q4 2026.
• Charlton previously served as SVP of clinical development, skeletal dysplasia at Tyra Biosciences.
• He also held chief medical officer roles, including at Spruce Biosciences, focused on pediatric rare-disease development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609010830PRIMZONEFULLFEED9819213) on September 01, 2026, and is solely responsible for the information contained therein.